Andriol Testocaps


Manufacturer: Healing Pharma
Substance: Testosterone Undecanoate
Packaging: 40 mg / caps. (30 caps.)

Manufacturer: Healing Pharma
Substance: Testosterone Undecanoate
Packaging: 40 mg / caps. (60 caps.)



General information about Nebido in Italy

Nebido is an extremely large testosterone/long ster complex that is primarily used in the treatment of low testosterone levels. Composed of Testosterone Undecanoate, this is the same hormone and ester used in the anabolic steroid Andriol, an oral testosterone capsule. However, Nebido is an injectable testosterone hormone and has a much longer post-dose activity time. Nebido is a relatively new anabolic steroid that was first launched on the market in 2004 by Schering AG. It has been approved for the treatment of androgen deficiency in most countries of the world.

Characteristics of Nebido in Italy

However, in the United States, the pharmaceutical company Indevus owns the rights to the Nebido line, and has not yet obtained full FDA approval in the United States, which may very well change in the near future, and there is no a logical reason for this, however, Nebido had a difficult time getting approval from the US FDA for reasons that are somewhat unknown. Although primarily seen as a testosterone compound for the treatment of low testosterone levels, Nebido can be used for performance enhancement. However, it is not as common among athletes and gym rats due to its very slow-acting nature. Results could easily be achieved with this most popular testosterone-like compound of Testosterone Cypionate and Testosterone Enanthate.

Interaction with other drugs in Italy

Description: The usual dose of Nebido is a 1000 mg injection slowly injected into the buttock muscle every 10-14 weeks.Testosterone is gradually released all the time from the depot into the blood and is effective for a long time. The exact dose and schedule must be determined by the doctor.


There are no reviews yet.

Be the first to review “Andriol Testocaps”

Your email address will not be published. Required fields are marked *